<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Donovan LM</submitter><funding>NHLBI NIH HHS</funding><pagination>1151-1157</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6812159</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(9)</volume><pubmed_abstract>Rationale: Symptoms of insomnia and anxiety are common among patients with chronic obstructive pulmonary disease (COPD), especially among patients with comorbid mental health disorders such as post-traumatic stress disorder (PTSD). Benzodiazepines provide temporary relief of these symptoms, but guidelines discourage routine use of benzodiazepines because of the serious risks posed by these medications. A more thorough understanding of guideline-discordant benzodiazepine use will be critical to reduce potentially inappropriate prescribing and its associated risks.Objectives: Examine the national prevalence, variability, and center correlates of long-term benzodiazepine prescriptions for patients with COPD and comorbid PTSD.Methods: We identified patients with COPD and PTSD between 2010 and 2012 who received care within the Department of Veterans Affairs. We used a mixed-effects logistic regression model to assess center predictors of long-term benzodiazepine prescriptions (≥90 d), while accounting for patient characteristics.Results: Of 43,979 patients diagnosed with COPD and PTSD at 129 centers, 24.4% were prescribed benzodiazepines long term, with use varying from 9.5% to 49.4% by medical center. Patients with long-term prescriptions were more likely to be white (90.1% vs. 80.7%) and have other mental health comorbidities, including generalized anxiety disorder (31.3% vs. 16.5%). Accounting for patient mix and characteristics, long-term benzodiazepine use was associated with lower patient-reported access to mental health care (odds ratio, 0.54; 95% confidence interval, 0.37-0.80).Conclusions: Long-term benzodiazepine prescribing is common among patients at high risk for complications, although this practice varies substantially from center to center. Poor access to mental health care is a potential driver of this guideline inconsistent use.</pubmed_abstract><journal>Annals of the American Thoracic Society</journal><pubmed_title>Center Predictors of Long-Term Benzodiazepine Use in Chronic Obstructive Pulmonary Disease and Post-traumatic Stress Disorder.</pubmed_title><pmcid>PMC6812159</pmcid><funding_grant_id>K12 HL137940</funding_grant_id><pubmed_authors>Donovan LM</pubmed_authors><pubmed_authors>Spece LJ</pubmed_authors><pubmed_authors>Malte CA</pubmed_authors><pubmed_authors>Feemster LC</pubmed_authors><pubmed_authors>Hawkins EJ</pubmed_authors><pubmed_authors>Au DH</pubmed_authors><pubmed_authors>Griffith MF</pubmed_authors><pubmed_authors>Zeliadt SB</pubmed_authors></additional><is_claimable>false</is_claimable><name>Center Predictors of Long-Term Benzodiazepine Use in Chronic Obstructive Pulmonary Disease and Post-traumatic Stress Disorder.</name><description>Rationale: Symptoms of insomnia and anxiety are common among patients with chronic obstructive pulmonary disease (COPD), especially among patients with comorbid mental health disorders such as post-traumatic stress disorder (PTSD). Benzodiazepines provide temporary relief of these symptoms, but guidelines discourage routine use of benzodiazepines because of the serious risks posed by these medications. A more thorough understanding of guideline-discordant benzodiazepine use will be critical to reduce potentially inappropriate prescribing and its associated risks.Objectives: Examine the national prevalence, variability, and center correlates of long-term benzodiazepine prescriptions for patients with COPD and comorbid PTSD.Methods: We identified patients with COPD and PTSD between 2010 and 2012 who received care within the Department of Veterans Affairs. We used a mixed-effects logistic regression model to assess center predictors of long-term benzodiazepine prescriptions (≥90 d), while accounting for patient characteristics.Results: Of 43,979 patients diagnosed with COPD and PTSD at 129 centers, 24.4% were prescribed benzodiazepines long term, with use varying from 9.5% to 49.4% by medical center. Patients with long-term prescriptions were more likely to be white (90.1% vs. 80.7%) and have other mental health comorbidities, including generalized anxiety disorder (31.3% vs. 16.5%). Accounting for patient mix and characteristics, long-term benzodiazepine use was associated with lower patient-reported access to mental health care (odds ratio, 0.54; 95% confidence interval, 0.37-0.80).Conclusions: Long-term benzodiazepine prescribing is common among patients at high risk for complications, although this practice varies substantially from center to center. Poor access to mental health care is a potential driver of this guideline inconsistent use.</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Sep</publication><modification>2024-10-18T06:09:54.704Z</modification><creation>2020-09-04T07:06:42Z</creation></dates><accession>S-EPMC6812159</accession><cross_references><pubmed>31113231</pubmed><doi>10.1513/annalsats.201901-048oc</doi><doi>10.1513/AnnalsATS.201901-048OC</doi></cross_references></HashMap>